TITLE

WYETH'S TORISEL APPROVED BY EUROPEAN COMMISSION

PUB. DATE
October 2009
SOURCE
Worldwide Biotech;Oct2009, Vol. 21 Issue 10, p8
SOURCE TYPE
Trade Publication
DOC. TYPE
Article
ABSTRACT
The article reports that the mammalian target of rapamycin (mTOR ) inhibitor TORISEL (R) (temsirolimus) has been approved by the European Commission for the treatment of adult patients with relapsed and/or refractory mantle cell lymphoma (MCL). Torisel is said to be used for the first-line treatment of patients with advanced renal cell carcinoma. It looks at TORISEL as an important option for the allegedly difficult-to-treat disease, relapsed and refractory mantle cell lymphoma.
ACCESSION #
44276418

 

Related Articles

  • Progression-free survival 'doubles' in renal cell carcinoma. Fricker, Janet // British Journal of Hospital Medicine (17508460);Oct2008, Vol. 69 Issue 10, p555 

    The article provides information on the update of the phase III Record 1 study presented at the European Society for Medical Oncology (ESMO), regarding the therapeutic use of RAD001, a once-daily oral therapy inhibiting the M-TOR or mammalian target of rapamycin protein in treating cancer. It...

  • YM155 reverses rapamycin resistance in renal cancer by decreasing survivin. Koike, Hidekazu; Nitta, Takashi; Sekine, Yoshitaka; Arai, Seiji; Furuya, Yosuke; Nomura, Masashi; Matsui, Hiroshi; Shibata, Yasuhiro; Ito, Kazuto; Oyama, Tetsunari; Suzuki, Kazuhiro // Journal of Cancer Research & Clinical Oncology;Oct2014, Vol. 140 Issue 10, p1705 

    Purpose: Mammalian target of rapamycin inhibitor has exhibited promising anticancer activity for the treatment of renal cell carcinoma (RCC). However, many patients acquire resistance to therapeutic agents leading to treatment failure. The objective of this study was to determine whether...

  • Safety and efficacy of the combination of erlotinib and sirolimus for the treatment of metastatic renal cell carcinoma after failure of sunitinib or sorafenib. Flaig, T. W.; Costa, L. J.; Gustafson, D. L.; Breaker, K.; Schultz, M. K.; Crighton, F.; Kim, F. J.; Drabkin, H. // British Journal of Cancer;9/7/2010, Vol. 103 Issue 6, p796 

    Background: The mammalian target of rapamycin (mTOR) is an important therapeutic target in the treatment of renal cell carcinoma (RCC). Pre-clinical data indicate that the combined inhibition of both the epidermal growth factor receptor and mTOR results in enhanced anticancer...

  • Targeted Therapies.  // Current Medical Literature: Kidney Cancer;Sep2009, Vol. 1 Issue 3, p74 

    The article focuses on the efficiency of sunitinib and Temsirolimus as treatment for renal cell carcinoma (RCC) pancreatic metastasis in Great Britain. The use of sunitinib as a therapeutic treatment has been viewed efficient after completing one remission (CR), four partial remissions (PR) in...

  • Eosinophilic Rash Secondary to Temsirolimus. Gandhi, Mona; Kuzel, Timothy; Lacouture, Mario // Clinical Genitourinary Cancer;Aug2009, Vol. 7 Issue 2, pE34 

    We present a case of a 73-year-old female with metastatic renal cell carcinoma, clear cell histologic subtype, who developed pruritic rash after 2 weeks of 25 mg weekly infusions of temsirolimus. Rash was located on bilateral antecubital areas and posterior knees. Skin biopsy showed spongiotic...

  • Renal Cell Cancer Treatments Have Similar Outcomes in Younger and Older Adults. Blakely, Michele D.; King, Cynthia R. // Oncology Nursing Forum;Sep2006, Vol. 33 Issue 5, p866 

    The article discusses research being done on renal cell cancer treatments in younger and older adults. It references a study by N. Berdjis et al published in the 2006 issue of "BJU International." It enumerates the factors that influence oncologic procedures and outcomes. Common comorbidities...

  • Renal Cell Carcinoma: The Translation of Molecular Biology Into New Treatments, New Patient Outcomes, and Nursing Implications. Moldawer, Nancy P.; Figlin, Robert // Oncology Nursing Forum;Jul2008, Vol. 35 Issue 4, p699 

    Purpose/Objectives: To provide an overview of the current knowledge and treatment options for renal cell carcinoma (RCC).Data Sources: Published articles, published abstracts, online databases, and package inserts.Data Synthesis: Researchers have an increased understanding of the genetic and...

  • A Phase II Study with 5-Fluorouracil, Folinic Acid and Oxaliplatin (FOLFOX-4 Regimen) in Patients with Metastatic Renal Cell Carcinoma. Bennouna, Jaafar; Delva, R.; Gomez, F.; Lesimple, T.; Geoffrois, L.; Linassier, C.; Chevreau, C.; Douillard, J. Y.; NĂ©grier, S. // Oncology;2003, Vol. 64 Issue 1, p25 

    Purpose: To investigate the efficacy and safety of the FOLFOX-4 regimen for patients with metastatic renal cell carcinoma (MRCC). Patients and Methods: Fifty-nine patients (median age 59 years) pre-treated or not by cytokines (29 vs. 30) received the FOLFOX-4 regimen every 2 weeks. Results:...

  • Chemotherapy in clear cell sarcoma. Jones, Robin; Constantinidou, Anastasia; Thway, Khin; Ashley, Sue; Scurr, Michelle; Al-Muderis, Omar; Fisher, Cyril; Antonescu, Cristina; D'Adamo, David; Keohan, Mary; Maki, Robert; Judson, Ian // Medical Oncology;Sep2011, Vol. 28 Issue 3, p859 

    Clear cell sarcoma is a rare translocation-related sarcoma. There have been few studies documenting the response rate and progression-free survival in clear cell sarcoma patients treated with palliative chemotherapy. The prospectively maintained databases of two referral centres were searched to...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics